T1	Participants 69 100	advanced, life-limiting illness
T2	Participants 147 178	patients with limited prognosis
T3	Participants 389 426	patients with limited life expectancy
T4	Participants 528 567	patients in the palliative care setting
T5	Participants 701 958	adults with an estimated life expectancy of between 1 month and 1 year, statin therapy for 3 months or more for primary or secondary prevention of cardiovascular disease, recent deterioration in functional status, and no recent active cardiovascular disease
